{"entity":{"id":"nct06218888","kind":"trial","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro","aka":[],"tldr":"A phase 2 trial of tislelizumab, fruquintinib and tucidinostat (chidamide) in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.","summary":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases is a phase 2, interventional study registered as NCT06218888 by Fujian Cancer Hospital, with a registry enrolment figure of 17 participants, started 2024-06-01 and due to reach its primary completion in 2025-12-01. Interventions recorded: Tislelizumab; Fruquintinib; Chidamide. Conditions listed: Colo-rectal Cancer. Primary outcome: Objective Response Rate（ORR）. Colorectal eligibility wording from the registry: \"* Subjects with histologically and/or cytologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma with liver metastasis (excluding adenosquamous carcinoma mixed with other pathological types)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06218888","url":"https://clinicaltrials.gov/study/NCT06218888"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["tislelizumab","fruquintinib","tucidinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06218888","phase":"2","setting":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases","sponsor":"Fujian Cancer Hospital","enrolled":17,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06218888/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}